Abstract
This investigation of fluvoxamine and fluoxetine-norfluoxetine distributions in vivo at steady-state and of quantitative kinetics in brain and plasma after drug therapy interruption was performed by fluorine nuclear magnetic resonance spectroscopy (19F MRS), spectroscopic imaging (MRSI), and plasma HPLC on 12 subjects treated for depression. MRSI suggests a homogeneous distribution of 19F MRS visible fluvoxamine mainly in brain. Fluvoxamine steady-state brain concentrations (12 ± 5 μM; n = 13) and brain-to-plasma concentration ratios (10 ± 2; n = 12) were similar to those of combined fluoxetine-norfluoxetine (CF-norfluoxetine) (13 ± 6 μM; n = 4 and 10 ± 6; n = 4). Fluvoxamine brain elimination half-life (79 ± 24 hours; n = 4) was significantly shorter than that of CF-norfluoxetine (382 ± 48 hours; n = 2). Fluvoxamine brain-to-plasma-half-life-ratio was 2.2 ± 0.3 (n = 4), contrarily to CF-norfluoxetine (1.0 ± 0.3; n = 2). This study shows that quantitative pharmacokinetics in target organs by 19F MRS in vivo should prove useful for understanding and investigating outcome of treatment modifications and side effects.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Altamura AC, Moro A, Percudani M . (1994): Clinical pharmacokinetics of fluoxetine. Drug Dispo 26 (3)): 201–214
Bolo NR, Hodé Y, Macher JP . (1996): Comparison of plasma and in-vivo brain levels of fluvoxamine measured by fluorine NMR spectroscopy during drug washout. In Proceedings of the International Society for Magnetic Resonance in Medicine; New York, NY, 2: 1179
Bolo NR, Hodé Y, Hennel F, Nédélec JJ, Lainey E, Macher JP . (1997): Localization of fluvoxamine signal in-vivo by fluorine chemical shift imaging at 3T. In Proceedings of the International Society for Magnetic Resonance in Medicine. Vancouver, Canada, 2: 1431
Brown TR, Kincaid BM, Ugurbil K . (1982): NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci USA. 79: 3523–3526
De Vries MH, Van Harten J, Van Bemmel P, Raghoebar M . (1993): Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Disp 14: 291–296
Durst P, Schuff N, Crocq MA, Mokrani MC, Macher JP . (1990): Non-invasive in-vivo detection of a fluorinated neuroleptic in the human brain by 19F nuclear magnetic resonance spectroscopy. Psychiatry Res Neuroimag 35: 107–114
GraphPad-Prism. (1995): Graph Pad Software Inc. Version 2.00.
Karson CN, Newton JEO, Mohanakrishnan P, Sprigg J, Komoroski RA . (1992): Fluoxetine and trifluoperazine in human brain: A 19F -nuclear magnetic resonance spectroscopy study. Psychiatry Res Neuroimag 45 (2)): 95–104
Karson CN, Newton JEO, Livingston R, Jolly JB, Cooper TB, Komoroski RA . (1993): Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 5: 322–329
Kelly MJ, Perry PJ, Holstad SG, Garvey MJ . (1989): Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Therap Drug Monit 11: 165–170
Komoroski RA, Newton JEO, Cardwell D, Sprigg J, Pearce J, Karson CN . (1994): In vivo19F spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn Res Med 31: 204–211
Komoroski RA, Newton JEO, Karson C, Cardwell D, Sprigg J . (1990): Detection of psychoactive drugs in vivo in humans using 19F NMR spectroscopy. Biol Psychiatry 29: 711–714
Miner CM, Davidson JR, Potts NL, Tupler LA, Charles HC, Krishnan KR . (1995): Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Biol Psychiatry 38: 696–698
Palmer KJ, Benfield P . (1994): Fluvoxamine. An overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1 (1)): 57–87
Renshaw PF, Guimares AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG, Puopolo PR, Clancy K, Gonzalez RG . (1992): Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry 149: 1592–1594
Strauss WL, Layton ME, Hayes CE, Dager SR . (1997): 19F magnetic resonance spectroscopy investigation in vivo of acute and steady state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry 154 (4)): 516–522
Strauss WL, Layton ME, Dager SR . (1998): Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry 155 (3)): 380–384
Weiss G, Ferretti J . (1983): Accuracy and precision in the estimation of peak areas and NOE factors. J Magn Res 55: 397–407
Wilde MI, Plosker GL, Benfield P . (1993): Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 46 (5)): 895–924
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bolo, N., Hodé, Y., Nédeléc, JF. et al. Brain Pharmacokinetics and Tissue Distribution In Vivo of Fluvoxamine and Fluoxetine by Fluorine Magnetic Resonance Spectroscopy. Neuropsychopharmacol 23, 428–438 (2000). https://doi.org/10.1016/S0893-133X(00)00116-0
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(00)00116-0
Keywords
This article is cited by
-
G protein-biased LPAR1 agonism of prototypic antidepressants: Implication in the identification of novel therapeutic target for depression
Neuropsychopharmacology (2024)
-
SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids
Translational Psychiatry (2023)
-
Differential and paradoxical roles of new-generation antidepressants in primary astrocytic inflammation
Journal of Neuroinflammation (2021)
-
Redox metabolism modulation as a mechanism in SSRI toxicity and pharmacological effects
Archives of Toxicology (2020)
-
Toward 19F magnetic resonance thermometry: spin–lattice and spin–spin-relaxation times and temperature dependence of fluorinated drugs at 9.4 T
Magnetic Resonance Materials in Physics, Biology and Medicine (2019)
